Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)
Q-fever is a zoonosis caused by Coxiella burnetii, an intracellular bacterium. Since the epidemic outbreak of acute Q-fever in Holland nearly 4030 people have been registered with the acute form of the disease. Knowing that only 40% of all infected people develop symptoms, the number of infected people (and potential candidates for chronic Q-fever) are much higher. Chronic Q-fever generally manifest itself after a couple of months or years after the primary infection (in 1-5% of all cases). The clinical presentation can be a life-threatening and frequently underdiagnosed disease, as endocarditis, infected aneurysm and vascular prosthesis or chronic Q-fever related to pregnancy and immunecompromised patients. That's why a screening program is started in the endemic area and trace patients with chronic Q-fever. So eventually, a greater group of patients with chronic vascular Q-fever can be described. In addition, there is still no therapeutic guideline for management of chronic Q-fever in patient with a vascular chronic Q-fever.
Patients with an aneurysm or vascular graft will be screened for chronic Q-fever. Patients with chronic Q-fever will be included in a follow-up program, in which additional research and treatment will start. The initial treatment of patients with chronic Q-fever is doxycycline and hydroxychloroquine for at least 18 months. In addition, patients will be monitored in 3-monthly controls, blood samples and imaging will be done. Parameters as complaints, titers, circulating DNA, grow of aneurysm, complications etc. will be investigated.
Ultimately, the current therapeutic guideline for management of C. burnetii will be evaluated if it can also be applied for patients with vascular chronic Q-fever.
Aortic Aneurysm, Abdominal
Vascular Graft Infection
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)|
- Treatment for patients with vascular chronic Q-fever [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]The current therapeutic guideline for chronic Q-fever, doxycycline and hydrochloroquine, will now be evaluated in patients with vascular chronic Q-fever
- Prevalence past resolved Q-fever [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- Symptomatology in patients with vascular chronic Q-fever [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- Additional value of the PET/CT-scan as diagnostic tool in patients with an infected aneurysm or vascular graft [ Time Frame: 1,5 years ] [ Designated as safety issue: Yes ]
- Grow of aneurysm in patients with a vascular chronic Q-fever [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
- Surgical intervention in patients with vascular chronic Q-fever [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]What number of patients with C.burnetii vascular infection develop an indication for surgery, why and what sort of prosthesis must be used. If a prosthesis is infected, should it be removed or not.
- Mortality [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
- Conversion rate to chronic Q-fever [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
Blood and tissue will be investigated using Polymerase Chain Reaction. Serology for C.burnetii will be investigated in blood using Immunofluorecense assay (focus diagnostics).
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||March 2014|
|Estimated Primary Completion Date:||March 2014 (Final data collection date for primary outcome measure)|
Patients with vascular chronic Q-fever
All patients with chronic Q-fever and an aneurysm or vascular reconstruction
Prospective observational survey
Patients with an abdominal aneurysm or central vascular reconstruction in an endemic area after an outbreak of acute Q-fever.
In Jeroen Bosch Hospital and Bernhoven Hospital all patients with an aneurysm or central vascular reconstruction will be screened for Q-fever. Other hospitals in Holland will only check for Q-fever, if they suspect a patient of having an infected aneurysm or prosthesis.
A patient with chronic Q-fever will enter a multidisciplinary follow-up program. First, a PET/CT-scan will be provided (question; signs of an infected aneurysm/prosthesis)and chronic Q-fever endocarditis will be excluded. The patients will initially be treated with doxycycline 2 dd 100mg and plaquenil 200mg 3dd for at least 18 months. A 3-monthly follow-up will start, in which bloodsample, ultrasounds and PET/CTscan will be performed. Data will be collected in SPSS for analyses.
Definitions; Past resolved Q-fever: Any IgG phase 2 and IgG phase 1 <1:1024 Chronic Q-fever: IgG phase 1 >= 1:1024
|Hospital Rijnstate||Not yet recruiting|
|Arnhem, Gelderland, Netherlands, 6815 AD|
|Contact: Steven van Sterkenburg firstname.lastname@example.org|
|Hospital Gelderse Vallei||Not yet recruiting|
|Ede, Gelderland, Netherlands, 6716 RP|
|Contact: Eric Ponfoort email@example.com|
|Elisabeth Hospital||Not yet recruiting|
|Tilburg, Noord Brabant, Netherlands, 5022 GC|
|Contact: Patrick Vriens firstname.lastname@example.org|
|Veghel/Oss, Noord Brabant, Netherlands, 5460 WB|
|Contact: André S van Petersen, MD email@example.com|
|Maxima Medical Centre||Not yet recruiting|
|Veldhoven, Noord Brabant, Netherlands, 5500 MB|
|Contact: Marc Scheltinga firstname.lastname@example.org|
|Jeroen Bosch Hospital||Recruiting|
|'s Hertogenbosch, Noord- Brabant, Netherlands, 5200 WB|
|Contact: Julia C.J.P. Hagenaars, MD 0031 (0) 735533652 email@example.com|
|Contact: Peter C Wever, MD, PhD firstname.lastname@example.org|
|Principal Investigator: Julia C.J.P. Hagenaars, MD|
|Antonius Hospital||Not yet recruiting|
|Nieuwegein, Utrecht, Netherlands, 3435 CM|
|Contact: Jean Paul de Vries email@example.com|
|Principal Investigator:||Julia C.J.P. Hagenaars, MD||Jeroen Bosch Hospital|